Fulvestrant (Page 6 of 6)

16 HOW SUPPLIED/STORAGE AND HANDLING

Fulvestrant Injection is supplied as two 5 mL clear glass (Type 1) syringes fitted with a removable tip cap, each containing 250 mg per 5 mL of Fulvestrant Injection solution for intramuscular use.

Product Code Unit of Sale Strength Each
760105 NDC 63323-715-05Unit of 2 250 mg per 5 mL(50 mg per mL) NDC 63323-715-015 mL Single-DosePre-filled Syringe

The pre-filled syringes with attached plunger rods are presented in a tray with two pre-packaged safety needles (SafetyGlide) for connection to the syringes.

Discard each syringe after use. If a patient dose requires only one syringe, unused syringe should be stored as directed below.

Storage:

Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) [USP Controlled Room Temperature].

Do not freeze. Do not use Fulvestrant Injection if it has been frozen. To protect from light, store in the original carton until time of use.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Monotherapy

Risk of Bleeding:

  • Because Fulvestrant Injection is administered intramuscularly, it should be used with caution in patients with bleeding disorders, decreased platelet count, or in patients receiving anticoagulants (for example, warfarin) [see Warnings and Precautions (5.1)].

Embryo-Fetal Toxicity:

  • Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with Fulvestrant Injection and for one year after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1), (8.3)].

Lactation:

  • Advise women not to breastfeed during treatment with Fulvestrant Injection and for one year after the last dose [see Use in Specific Populations (8.2)].

Combination Therapy

When Fulvestrant Injection is used in combination with palbociclib, abemaciclib, or ribociclib, refer to the respective Full Prescribing Information for Patient Counseling Information.

Manufactured for:

Fresenius Kabi Logo

Lake Zurich, IL 60047
www.fresenius-kabi.com/usMade in Austria

451542D

PATIENT INFORMATION Fulvestrant (ful-VES-trant)Injection
What is Fulvestrant Injection? Fulvestrant Injection is a prescription medicine used to treat advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic).Fulvestrant Injection may be used alone, if you have gone through menopause, and your advanced breast cancer is:
  • hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative and has not been previously treated with endocrine therapy or
  • HR-positive and has progressed after endocrine therapy.
Fulvestrant Injection may be used in combination with ribociclib, if you have gone through menopause, and your advanced or metastatic breast cancer is HR-positive and HER2-negative, and has not been previously treated with endocrine therapy or has progressed after endocrine therapy.Fulvestrant Injection may be used in combination with palbociclib or abemaciclib if your advanced or metastatic breast cancer is HR-positive and HER2-negative, and has progressed after endocrine therapy.When Fulvestrant Injection is used in combination with palbociclib, abemaciclib, or ribociclib, also read the Patient Information for the prescribed product.It is not known if Fulvestrant Injection is safe and effective in children.It is not known if Fulvestrant Injection is safe and effective in people with severe liver problems.
Who should not receive Fulvestrant Injection? Do not receive Fulvestrant Injection if you have had an allergic reaction to fulvestrant or any of the ingredients in Fulvestrant Injection. See the end of this leaflet for a list of the ingredients in Fulvestrant Injection.Symptoms of an allergic reaction to Fulvestrant Injection may include:
  • itching or hives
  • swelling of your face, lips, tongue, or throat
  • trouble breathing
What should I tell my healthcare provider before receiving Fulvestrant Injection? Before receiving Fulvestrant Injection, tell your healthcare provider about all of your medical conditions, including if you:
  • have a low level of platelets in your blood or bleed easily.
  • have liver problems.
  • are pregnant or plan to become pregnant.
  • Fulvestrant Injection can harm your unborn baby. Females who are able to become pregnant:
    • Your healthcare provider may perform a pregnancy test within 7 days before you start Fulvestrant Injection.
    • You should use effective birth control during treatment with Fulvestrant Injection and for one year after the last dose of Fulvestrant Injection.
    • Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Fulvestrant Injection.
  • are breastfeeding or plan to breastfeed. It is not known if Fulvestrant Injection passes into your breast milk. Do not breastfeed during your treatment with Fulvestrant Injection and for one year after the last dose of Fulvestrant Injection. Talk to your healthcare provider about the best way to feed your baby during this time.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Fulvestrant Injection may affect the way other medicines work, and other medicines may affect how Fulvestrant Injection works.Especially tell your healthcare provider if you take a blood thinner medicine.
How will I receive Fulvestrant Injection?
  • Your healthcare provider will give you Fulvestrant Injection by injection into the muscle of each buttock.
  • Your healthcare provider may change your dose of Fulvestrant Injection if needed.
What are the possible side effects of Fulvestrant Injection? Fulvestrant Injection may cause serious side effects, including:
  • Injection site related nerve damage. Call your healthcare provider if you develop any of the following symptoms in your legs following a Fulvestrant Injection:
    • numbness
    • tingling
    • weakness
The most common side effects of Fulvestrant Injection include:
  • injection site pain
  • nausea
  • muscle, joint, and bone pain
  • headache
  • back pain
  • tiredness
  • pain in arms, hands, legs, or feet
  • hot flashes
  • vomiting
  • loss of appetite
  • weakness
  • cough
  • shortness of breath
  • constipation
  • increased liver enzymes
  • diarrhea
Fulvestrant Injection may cause fertility problems in males and females. Talk to your healthcare provider if you plan to become pregnant.Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects with Fulvestrant Injection. For more information, ask your healthcare provider or pharmacist.Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA1088.
General information about the safe and effective use of Fulvestrant Injection. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Fulvestrant Injection that is written for health professionals.

What are the ingredients in Fulvestrant Injection? Active ingredient: fulvestrant.Inactive ingredients: dehydrated alcohol, benzyl alcohol, polysorbate 80, alpha-tocopherol, and castor oil.SafetyGlideTM is a trademark of Becton Dickinson and Company. Manufactured for:Fresenius Kabi Logo
Lake Zurich, IL 60047Made in Austria451556CRevised: September 2021For more information, go to www.fresenius-kabi.com/us or call 1-800-551-7176.This Patient Information has been approved by the U.S. Food and Drug Administration.

Principal Display Panel – Fulvestrant Injection 250 mg per 5 mL Syringe Carton Panel

For Single-Dose Only NDC 63323-715-05

Fulvestrant Injection

250 mg per 5 mL (50 mg per mL)

For intramuscular use only.

Principal Display Panel – Fulvestrant Injection 250 mg per 5 mL Syringe Carton Panel
(click image for full-size original)

Principal Display Panel – Fulvestrant Injection 250 mg per 5 mL Syringe Label

NDC 63323-715-01

Fulvestrant Injection

250 mg per 5 mL (50 mg per mL)

For intramuscular use only.

Principal Display Panel – Fulvestrant Injection 250 mg per 5 mL Syringe Label
(click image for full-size original)
FULVESTRANT fulvestrant injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:63323-715
Route of Administration INTRAMUSCULAR DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Fulvestrant (Fulvestrant) Fulvestrant 50 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
Benzyl Alcohol
Polysorbate 80
.Alpha.-Tocopherol
Castor Oil
Alcohol
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:63323-715-05 2 SYRINGE, GLASS in 1 CARTON contains a SYRINGE, GLASS (63323-715-01)
1 NDC:63323-715-01 5 mL in 1 SYRINGE, GLASS This package is contained within the CARTON (63323-715-05)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA210326 05/20/2019
Labeler — Fresenius Kabi USA, LLC (608775388)
Establishment
Name Address ID/FEI Operations
Fresenius Kabi Austria 300206604 ANALYSIS (63323-715), MANUFACTURE (63323-715), PACK (63323-715)

Revised: 01/2024 Fresenius Kabi USA, LLC

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.